Aura Biosciences Inc expected to post a loss of 49 cents a share - Earnings Preview

Aura Biosciences

07/05/2025 14:09

Aura Biosciences Inc AURA.OQ AURA.O is expected to show no change in quarterly revenue when it reports  results on May 9 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Aura Biosciences Inc is for a loss of 49 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aura Biosciences Inc is $22.50​, above​ its last closing price of $5.47. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.45
-0.44
-0.52
Missed
-17.2
Sep. 30 2024
-0.44
-0.44
-0.42
Beat
4.7
Jun. 30 2024
-0.44
-0.45
-0.41
Beat
8.9​
Mar. 31 2024
-0.48
-0.49
-0.40
Beat
17.7
​​Dec. 31 2023
-0.44
-0.41
-0.56
Missed
-35.9
Sep. 30 2023
-0.53
-0.52
-0.48
Beat
7.8​
Jun. 30 2023
-0.49
-0.49
-0.48
Beat
2
Mar. 31 2023
-0.53
-0.54
-0.46
Beat
14.9

This summary was machine generated May 7 at 13:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)